Treatment of Facial Flushing With Botulinum Toxin A Injections
Treatment of Facial Flushing With Botulinum Toxin A Injections: A Split-Face, Double-blinded, Randomized Control Trial
The purpose of this study is to find out if botulinum toxin A (botox®) can be used to treat facial flushing.
This study is a pilot study designed to determine feasibility of these procedures.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients 18-65 years of age with persistent facial flushing
- Willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the study staff.
Exclusion Criteria:
- Unable to understand the protocol or give informed consent
- Younger than 18 or older than 65 years of age
- Females who are pregnant or lactating
- Known hypersensitivity to BTX-A
- Subjects using medications that interfere with neuromuscular functions (such as aminoglycoside antibiotics)
- Subjects who have a history of congestive heart failure, carcinoid syndrome, mastocystosis, or renal cell carcinoma
- Botulinum toxin injections in the past 6 months
- Ablative laser procedure in the past 6 months
- Radiofrequency device treatment in the past 6 months
- Ultrasound device treatment in the past 6 months
- Medium to deep chemical peel in the past 6 months
- Temporary soft tissue augmentation material in the area to be treated in the past year
- Semi-permanent soft tissue augmentation material in the area to be treated in the past 2 years
- Permanent soft tissue augmentation material in the area to be treated
- Is planning to receive within the next 6 months, any cosmetic procedure (such as any chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound and face lifting procedures) in the forehead or glabellar region.
- Is planning to use tretinoin or retinoic acid in the next 6 months
- Has an active infection in the forehead or glabellar region (excluding mild acne)
- Is allergic to cow's milk protein
- Is allergic to albumin
- Is currently using anticoagulation therapy
- Has a history of bleeding disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: botulinum toxin A
This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side.
Only one side of the face will receive botox injections.
|
A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
Other Names:
|
|
Placebo Comparator: Saline Control
This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side.
Only one side of the face will receive botox injections.
|
A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spectrophotometer measurement
Time Frame: Baseline and 8 weeks
|
Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit
|
Baseline and 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Murad Alam, MD, Northwestern University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavior
- Communication
- Nonverbal Communication
- Blushing
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Botulinum Toxins
- Metalloendopeptidases
- Endopeptidases
- Peptide Hydrolases
- Metalloproteases
- Bacterial Proteins
- Bacterial Toxins
- Toxins, Biological
- Botulinum Toxins, Type A
Other Study ID Numbers
Other Study ID Numbers
- STU97514
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.